Compare · CSTL vs HUM
CSTL vs HUM
Side-by-side comparison of Castle Biosciences Inc. (CSTL) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CSTL and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $46.80B, about 43.8x CSTL ($1.07B).
- CSTL has been more active in the news (12 items in the past 4 weeks vs 6 for HUM).
- HUM has more recent analyst coverage (25 ratings vs 6 for CSTL).
- Company
- Castle Biosciences Inc.
- Humana Inc.
- Price
- -
- -
- Market cap
- $1.07B
- $46.80B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 12
- 6
- Recent ratings
- 6
- 25
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest CSTL
- Castle Biosciences to Participate in Upcoming Investor Conferences
- Chief Commercial Officer Juvenal Tobin W sold $51,191 worth of shares (1,730 units at $29.59) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 75,964 units (SEC Form 4)
- Chief Financial Officer Stokes Frank sold $741,511 worth of shares (24,908 units at $29.77), decreasing direct ownership by 41% to 35,177 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 1,100 shares at a strike of $2.39 and sold $217,105 worth of shares (7,232 units at $30.02) as part of a pre-agreed trading plan (SEC Form 4)
- Castle Biosciences Approved for Dual Listing on Nasdaq Texas
- SEC Form 144 filed by Castle Biosciences Inc.
- SEC Form 8-A12B filed by Castle Biosciences Inc.
- Chief Commercial Officer Juvenal Tobin W sold $49,945 worth of shares (1,301 units at $38.39) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 77,694 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 22,902 shares at a strike of $2.39 and sold $1,212,230 worth of shares (39,016 units at $31.07) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Oelschlager Kristen M sold $255,622 worth of shares (8,586 units at $29.77) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 13,288 units (SEC Form 4)
Latest HUM
- Humana Names Dr. Shantanu Nundy as Chief Medical Officer
- James P. Holland to Join Humana as Medicaid President
- Humana upgraded by Morgan Stanley with a new price target
- Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
- Director Smith Paul John was granted 544 units of Humana Common (SEC Form 4)
- Director Crawford Frederick John was granted 544 units of Humana Common (SEC Form 4)
- Humana upgraded by Evercore ISI with a new price target
- Humana upgraded by Leerink Partners with a new price target
- Humana downgraded by Raymond James
- New insider Crawford Frederick John claimed ownership of 21 units of Humana Common (SEC Form 3)